It is reassuring to note that clinical trial data from the STEP programme (using dual-energy X-ray absorptiometry) indicate that fat loss predominates with semaglutide 2.4 mg
MOTS-c works at the source of a specific metabolic problem: the decline in mitochondrial function and insulin sensitivity that makes fat accumulation, particularly visceral fat accumulation, increasingly resistant to conventional interventions as patients age
Recent studies have suggested the potential benefits of SGLT2 inhibitors, including empagliflozin, in slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes, and reducing the risk of cardiovascular events.The decision to use empagliflozin in CKD should be made on a case-by-case basis, considering the patients overall kidney function and potential risks
Chedraui, P., & Prez-Lpez, F
10.1002/glia.24109 Glia 67 LauS